-
How Valeant Finally Won Over A Longtime Bear
Monday, March 5, 2018 - 11:34am | 367Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) fell 20 percent after reporting in-line earnings results. But the very news that catalyzed a selloff was well-received by one longtime Valeant bear who transformed into a bull Monday. The Rating Deutsche Bank analyst Gregg Gilbert ...
-
Deutsche Bank Boosts Mylan's Price Target On This Scenario
Friday, April 24, 2015 - 3:18pm | 263Read More...In a report rolled out Friday, Deutsche Bank analysts Gregg Gilbert and Greg Fraser reiterated a Buy rating and raised their price target on shares of Mylan NV (NASDAQ: MYL) from $65 to $82. The new price target intends to reflect the initial offer to acquire the company that Teva Pharmaceutical...
-
Akorn Initiated At Deutsche Bank, Notes Impressive Drug Pipeline
Wednesday, April 8, 2015 - 9:43am | 197Read More...Deutsche Bank issued a company note on Akorn, Inc. (NASDAQ: AKRX) initiating coverage on the company. Deutsche Bank rates Akorn as a Buy with a $55 price target. Analysts Gregg Gilbert and Greg Fraser wrote, "For a midcap specialty generics company, Akorn has a relatively diverse revenue base,...
